Emese Zsiros, MD - Clinical Trial Investigator | Syfrah

Trials Sponsors Conditions Drugs Pricing

Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

MIXED(7)

BIOLOGICAL(3)

DRUG(3)

Laboratory Biomarker Analysis

early_phase_1phase_1phase_1_2

roswell-park-cancer-institute

Autologous NY-ESO-1-specific CD8-positive T Lymphocytes

roswell-park-cancer-institute

Cellular Therapy

roswell-park-cancer-institute

DEC-205/NY-ESO-1 Fusion Protein CDX-1401

roswell-park-cancer-institute

Genetically Engineered NY-ESO-1-specific T Lymphocytes

roswell-park-cancer-institute

Diagnostic Microscopy

roswell-park-cancer-institute

roswell-park-cancer-institute

roswell-park-cancer-institute

+3 more interventions

11 unique interventions3 categories

Analytics

Trial Phases

Phase 13

Phase 21

Trial Status

Completed2

Terminated1

Other1

Role Distribution

Principal Investigator4

PI Rate100%

Activity Timeline

Clinical Trials (4)

NCT03691376Phase 1Terminated

Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Platinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Ovarian CarcinomaPlatinum-Resistant Primary Peritoneal Carcinoma+9 more

PrincipalinvestigatorStart date: 2019-03-08

NCT03017131Phase 1Active Not Recruiting

Genetically Modified T Cells and Decitabine in Treating Patients With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Recurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal Carcinoma

PrincipalinvestigatorStart date: 2017-12-08

NCT03297489Early Phase 1Completed

Intravital Microscopy in Evaluating Patients With Primary Peritoneal, Fallopian Tube, or Stage IA-IV Ovarian Cancer

Fallopian Tube CarcinomaPrimary Peritoneal CarcinomaStage I Ovarian Cancer+12 more

PrincipalinvestigatorStart date: 2017-11-06

NCT02166905Phase 1/2Completed

DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission

Fallopian Tube CarcinomaOvarian CarcinomaPrimary Peritoneal Carcinoma

PrincipalinvestigatorStart date: 2014-10-10

Research Network

Collaboration Network

1 collaborators·0 connections

Network Legend

KOL

Current Investigator

CO

High-influence Collaborator

CO

Collaborator

Click: view details

Double-click: go to profile

Drag: move node

Research Areas & Affiliations

Therapeutic Areas

Fallopian Tube Carcinoma2 Primary Peritoneal Carcinoma2 Recurrent Fallopian Tube Carcinoma2 Recurrent Ovarian Carcinoma2 Recurrent Primary Peritoneal Carcinoma2 Ovarian Carcinoma1 Platinum-Resistant Fallopian Tube Carcinoma1 Platinum-Resistant Ovarian Carcinoma1

Affiliations

Roswell Park Cancer Institute

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Amir A Jazaeri

M.D. Anderson Cancer Center

Shared therapeutic areas:

Platinum-Resistant Ovarian CarcinomaRecurrent Ovarian CarcinomaPlatinum-Resistant Fallopian Tube Carcinoma+6 more

Worked with same sponsors:

National Cancer Institute (NCI)

Similarity Score10%

Lilie L Lin

M.D. Anderson Cancer Center

Shared therapeutic areas:

Recurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal Carcinoma+3 more

Worked with same sponsors:

National Cancer Institute (NCI)

Similarity Score6%

Russell Schilder

Gynecologic Oncology Group

Shared therapeutic areas:

Primary Peritoneal CarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Ovarian Carcinoma+2 more

Worked with same sponsors:

National Cancer Institute (NCI)

Similarity Score5%

Shannon N Westin

M.D. Anderson Cancer Center

Shared therapeutic areas:

Recurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal Carcinoma+1 more

Worked with same sponsors:

National Cancer Institute (NCI)

Similarity Score4%

Emese Zsiros

Roswell Park Cancer Institute

Shared therapeutic areas:

Recurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal Carcinoma+1 more

Worked with same sponsors:

Celldex TherapeuticsNational Cancer Institute (NCI)+1 more

Similarity Score4%

Shannon Westin

M.D. Anderson Cancer Center

Shared therapeutic areas:

Recurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal Carcinoma

Worked with same sponsors:

National Cancer Institute (NCI)

Similarity Score3%

Evanthia Galanis, MD

Mayo Clinic

Shared therapeutic areas:

Recurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal Carcinoma

Worked with same sponsors:

National Cancer Institute (NCI)

Similarity Score3%

Dennis Chi, MD

Memorial Sloan Kettering Cancer Center

Shared therapeutic areas:

Fallopian Tube CarcinomaOvarian CarcinomaPrimary Peritoneal Carcinoma

Similarity Score3%

Aung Naing, Md

M.D. Anderson Cancer Center

Shared therapeutic areas:

Fallopian Tube CarcinomaOvarian CarcinomaPrimary Peritoneal Carcinoma

Worked with same sponsors:

National Cancer Institute (NCI)

Similarity Score3%

David G Mutch, M.D.

Washington University School of Medicine

Shared therapeutic areas:

Ovarian CarcinomaPrimary Peritoneal Carcinoma

Worked with same sponsors:

National Cancer Institute (NCI)

Similarity Score2%

Publications (0)

No publications found for this investigator.

Clinical Trials (4)

Showing 4 of 4 trials

NCT03691376Phase 1PrincipalInvestigator

Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Platinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Ovarian CarcinomaPlatinum-Resistant Primary Peritoneal Carcinoma+9 more

Terminated

NCT03017131Phase 1PrincipalInvestigator

Genetically Modified T Cells and Decitabine in Treating Patients With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Recurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal Carcinoma

Active Not Recruiting

NCT03297489Early Phase 1PrincipalInvestigator

Intravital Microscopy in Evaluating Patients With Primary Peritoneal, Fallopian Tube, or Stage IA-IV Ovarian Cancer

Fallopian Tube CarcinomaPrimary Peritoneal CarcinomaStage I Ovarian Cancer+12 more

Completed

NCT02166905Phase 1/2PrincipalInvestigator

DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission

Fallopian Tube CarcinomaOvarian CarcinomaPrimary Peritoneal Carcinoma

Completed

All 4 trials loaded